Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

Erdafitinib (Balversa) had a predictable toxicity profile and showed early efficacy signals in patients with recurrent or progressive IDH wild-type glioma with FGFR-TACC (F3T3) gene fusions, according to findings from the safety run-in cohort of…